These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 363434)

  • 1. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
    Resnekov EB; Havard CW
    Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with a slow-release formulation of oxprenolol.
    Waal-Manning HJ; Spears GF
    N Z Med J; 1978 Apr; 87(609):245-6. PubMed ID: 275650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily.
    Olowoyeye JO; Thadani U; Parker JO
    Am J Cardiol; 1981 May; 47(5):1123-7. PubMed ID: 7223659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    Clin Sci Mol Med Suppl; 1976 Dec; 3():559s-561s. PubMed ID: 1071681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
    Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
    J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of oxprenolol and methyldopa in hypertension. A within-patient double-blind trial.
    Barritt DW; Marshall AJ; Heaton S
    Lancet; 1976 Mar; 1(7958):503-5. PubMed ID: 55780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.
    Wilcox RG; Hampton JR
    Br Heart J; 1981 Nov; 46(5):498-502. PubMed ID: 6119103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once daily beta-blocker in hypertension--oxprenolol slow-release.
    Gordon RD; Ziesak M; Rowe WS; Strakosch CR; Row G
    J Int Med Res; 1981; 9(1):6-11. PubMed ID: 7009256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a slow release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    N Z Med J; 1976 Aug; 84(570):142-4. PubMed ID: 1069924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial.
    Materson BJ; Friedman BA; Hla KM; Neidorf BS; Gray JM; Glazer N; Gross S
    Drug Intell Clin Pharm; 1983 Jan; 17(1):51-4. PubMed ID: 6337801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
    West MJ; Kendall MJ; Mitchard M; Faragher EB
    Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind study of oxprenolol once and twice daily in hypertensive patients.
    Glazer N; Friedman B; Gerlings E; Gross S; Lowney C; Solomon R
    Clin Cardiol; 1983 Aug; 6(8):378-83. PubMed ID: 6352119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
    Ravid M; Lang R; Jutrin I
    Arch Intern Med; 1985 Jul; 145(7):1321-3. PubMed ID: 4015285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.
    Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
    Eur J Clin Pharmacol; 1987; 32(2):127-33. PubMed ID: 3556193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre evaluation of sustained release oxprenolol in the management of hypertension in hospital out-patient practice.
    Forrest WA
    J Int Med Res; 1978; 6(2):136-40. PubMed ID: 631415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can once daily dosage be effective in the treatment of hypertension throughout 24 hours? A controlled evaluation of sustained release oxprenolol.
    Volan GN; Rogers HJ; House F
    Br J Clin Pharmacol; 1979 Jul; 8(1):86-9. PubMed ID: 399593
    [No Abstract]   [Full Text] [Related]  

  • 20. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.
    Petrie JC; Jeffers TA; Robb OJ; Scott AK; Webster J
    Br Med J; 1980 Jun; 280(6231):1573-4. PubMed ID: 7000243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.